GB2495491A - Pre-biotic skin wipe - Google Patents
Pre-biotic skin wipe Download PDFInfo
- Publication number
- GB2495491A GB2495491A GB1117415.8A GB201117415A GB2495491A GB 2495491 A GB2495491 A GB 2495491A GB 201117415 A GB201117415 A GB 201117415A GB 2495491 A GB2495491 A GB 2495491A
- Authority
- GB
- United Kingdom
- Prior art keywords
- webbing
- prebiotic
- flexible webbing
- skin
- text
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 49
- 229920001202 Inulin Polymers 0.000 claims abstract description 19
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 17
- 229940029339 inulin Drugs 0.000 claims abstract description 17
- 239000000835 fiber Substances 0.000 claims abstract description 14
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 13
- 150000003272 mannan oligosaccharides Chemical class 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims abstract description 5
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 4
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 4
- 239000000725 suspension Substances 0.000 claims abstract description 4
- 239000000463 material Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 17
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 12
- -1 polyethylene terephthalate Polymers 0.000 claims description 11
- 229920000297 Rayon Polymers 0.000 claims description 10
- 235000014633 carbohydrates Nutrition 0.000 claims description 10
- 244000005700 microbiome Species 0.000 claims description 10
- 229920002678 cellulose Polymers 0.000 claims description 8
- 239000001913 cellulose Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 230000001594 aberrant effect Effects 0.000 claims description 7
- 229920000742 Cotton Polymers 0.000 claims description 6
- 239000004698 Polyethylene Substances 0.000 claims description 6
- 229920002261 Corn starch Polymers 0.000 claims description 5
- 229920001131 Pulp (paper) Polymers 0.000 claims description 5
- 229920002301 cellulose acetate Polymers 0.000 claims description 5
- 239000008120 corn starch Substances 0.000 claims description 5
- 239000004952 Polyamide Substances 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 230000009286 beneficial effect Effects 0.000 claims description 4
- 229920002647 polyamide Polymers 0.000 claims description 4
- 229920000728 polyester Polymers 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 229920000098 polyolefin Polymers 0.000 claims description 4
- 239000002964 rayon Substances 0.000 claims description 4
- 229920002994 synthetic fiber Polymers 0.000 claims description 4
- 229920001328 Polyvinylidene chloride Polymers 0.000 claims description 3
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 3
- 239000004800 polyvinyl chloride Substances 0.000 claims description 3
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 3
- 239000005033 polyvinylidene chloride Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 2
- 229940064062 alpha-glucan oligosaccharide Drugs 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229920000139 polyethylene terephthalate Polymers 0.000 claims 1
- 239000005020 polyethylene terephthalate Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 abstract description 9
- 150000002482 oligosaccharides Chemical class 0.000 abstract description 9
- 239000000843 powder Substances 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 38
- 241000894006 Bacteria Species 0.000 description 10
- 230000008569 process Effects 0.000 description 8
- 206010012444 Dermatitis diaper Diseases 0.000 description 7
- 208000002474 Tinea Diseases 0.000 description 7
- 239000004745 nonwoven fabric Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 5
- 150000003271 galactooligosaccharides Chemical class 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 241000893966 Trichophyton verrucosum Species 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 230000003466 anti-cipated effect Effects 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 206010040872 skin infection Diseases 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 3
- 244000298479 Cichorium intybus Species 0.000 description 3
- 235000007542 Cichorium intybus Nutrition 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 206010017543 Fungal skin infection Diseases 0.000 description 3
- 240000008892 Helianthus tuberosus Species 0.000 description 3
- 235000003230 Helianthus tuberosus Nutrition 0.000 description 3
- 206010021639 Incontinence Diseases 0.000 description 3
- 208000010195 Onychomycosis Diseases 0.000 description 3
- 239000004752 air-laid paper Substances 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 210000002249 digestive system Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 201000005882 tinea unguium Diseases 0.000 description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 206010021531 Impetigo Diseases 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- 208000007027 Oral Candidiasis Diseases 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000130764 Tinea Species 0.000 description 2
- 208000007712 Tinea Versicolor Diseases 0.000 description 2
- 206010056131 Tinea versicolour Diseases 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 241000287411 Turdidae Species 0.000 description 2
- 241000212749 Zesius chrysomallus Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 229960004022 clotrimazole Drugs 0.000 description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000004013 groin Anatomy 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229960000988 nystatin Drugs 0.000 description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 201000000508 pityriasis versicolor Diseases 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- 230000006099 transfructosylation Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000009941 weaving Methods 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- QNTKVQQLMHZOKP-NEJDVEAASA-N (2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-2-[[(2r,3s,4s,5r)-2-[[(2r,3s,4s,5r)-2-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]- Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QNTKVQQLMHZOKP-NEJDVEAASA-N 0.000 description 1
- ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 description 1
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- ODEHMIGXGLNAKK-OESPXIITSA-N 6-kestotriose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 ODEHMIGXGLNAKK-OESPXIITSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 229920000310 Alpha glucan Polymers 0.000 description 1
- 241000837186 Andina granulosa Species 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- 206010072055 Botryomycosis Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N D-fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010015216 Erythema marginatum Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 229920002670 Fructan Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241001534204 Klebsiella pneumoniae subsp. rhinoscleromatis Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 1
- 206010028885 Necrotising fasciitis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- FLDFNEBHEXLZRX-DLQNOBSRSA-N Nystose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(O[C@@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FLDFNEBHEXLZRX-DLQNOBSRSA-N 0.000 description 1
- 244000215747 Pachyrhizus erosus Species 0.000 description 1
- 235000001591 Pachyrhizus erosus Nutrition 0.000 description 1
- 235000018669 Pachyrhizus tuberosus Nutrition 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 244000134540 Polymnia sonchifolia Species 0.000 description 1
- 235000003406 Polymnia sonchifolia Nutrition 0.000 description 1
- 208000021326 Ritter disease Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 206010041929 Staphylococcal scalded skin syndrome Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 206010067197 Tinea manuum Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- 150000004783 arabinoxylans Chemical class 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- WOHYVFWWTVNXTP-TWOHWVPZSA-N beta-D-fructofuranosyl-(2,1)-beta-D-fructofuranose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(O)CO[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 WOHYVFWWTVNXTP-TWOHWVPZSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 201000004308 chancroid Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940021231 clearskin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000009957 hemming Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000005005 intertrigo Diseases 0.000 description 1
- UVEIHXHNEIMXTD-VORSWSGSSA-N inulotriose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO[C@]1(CO[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O UVEIHXHNEIMXTD-VORSWSGSSA-N 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- FLDFNEBHEXLZRX-UHFFFAOYSA-N nystose Natural products OC1C(O)C(CO)OC1(CO)OCC1(OCC2(OC3C(C(O)C(O)C(CO)O3)O)C(C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 FLDFNEBHEXLZRX-UHFFFAOYSA-N 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229960002607 sulconazole Drugs 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229960002197 temoporfin Drugs 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/068—Microemulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a flexible webbing comprising at least one prebiotic. The prebiotic may be a carbohydrate or oligosaccharide, preferably asoluble fibre carbohydrate, fructooligosaccharide, galactooligosacharides or mannan oligosaccharides, more specifically inulin. The prebiotic may be a powder, liquid or suspension. The webbing may be biodegradable, non-biodegradable or both. Also disclosed is a kit for applying a prebiotic to a surface.
Description
PREBIOTIC WEBBING
This invention relates to prebiotic webbing, and more particularly the present inventLon relates to wipe or tissue comprising at least one prebiotic.
BACKGROUND
Skin including human skin plays a key role in protecting the body from pathogens, and comprises a dermal and an epidermal layer. In its normal healthy state the skin is a host for many different types of microorganisms which do not cause it harm. However under certain conditions such as for example when a person has recently taken a course of antibiotics, are taking steroids, have diabetes, are overweight, have had thngal skin infections in the past, have a weakened immune system caused, for example, by cancer or HIV/AIDS, or the skin has suffered trauma, wound or abrasion the skin can be subjected to aberrant skin infection in the form of viral infection, flingal infection and bacterial infection. Left untreated in some instances these infections can become life threatening.
For example common thngal infections of the skin include Athlete's foot (Tinea ped[s and Tinea manuum) is caused by a combination of fringi and bacteria, causing your skin to become itchy, dry, scaly and red, especially between your toes; Onychomycosis is the name for any fungal nail infection. Tinea unguium ringworm of your nails) is a common infection; Ringworm of the groin (Tinea eruris) causes an itchy, red rash in your groin and the surrounding area; Ringworm on the body (Tinea corporis) This often affects exposed areas of your body, such as your abdomen (tummy) or your limbs, causing red raised or flat patches and rings that can merge, grow and spread. The rings are scaly at the edge with clear skin at the centre; lntertrigo is a yeast infection of skin folds caused by the fungus Candida albicans, which lives on your skin and in your digestive system; Pityriasis versicolor is a yeast infection causes dark patches to form on pale or nntanned skin and light patches on tanned or darker skin; Thrush (Candida albicans) usually lives in harmony with us and rardy causes problems. However, in certain situations, such as if you're ill, have poorly controlled diabetes, are pregnant or using antibiotics, the fungi multiply and cause problems.
The most common bacteria to cause skin infections arc: Staphylococcus aureus which causes conditions such as Folliculitis, Furunculosis (boils), Impetigo, Staphylococcal scalded skin syndrome, and Botryomycosis (pyodcrma vcgctans) ; Streptococcus pvogenes which causes Cellulitis, Erysipclas, Impetigo, Necrotising fasciitis, Rheumatic fever, erythema marginatum.
Other less common bacterial skin conditions are for example Haemophilus species, cause of chancroid and cellulitis in young children Helicohacterpylori; Klebsiella rhinoscieroinatis, cause of rhino seleroma.
It is often the case that these conditions are treated with anti-fungal medicines (e.g. clotrimazole, Econazoic, ketoconazole, miconazole, sulconazoe, nystatin), steroids such as corticosteroids and antibiotics.
Nappy rash is a common condition thought to affect up to a third of nappy-wearing babies at any given time. It causes the baby's skin to become sore and irritated in the area around the nappy, and covered in pink or red spots or blotches. Nappy rash is usually caused by your baby's skin coming into contact with urine and faeces in their nappy and can be a cause of a bacterial or fungal skin infection. Similar problems are associated with juveniles and adults who suffer from incontinent. One commonly used means to prevent infection of the skin where nappy rash is like'y to occur is to protect that area of the skin with a barrier cream such as zinc oxide based creams. In more severe cases it may be necessary to treat the condition with medicaments described above.
However, the above treatments all rely on either a skin barrier being formed that prevents infection or the treatment of an infection with an antiseptic or mcdicament. It is therefore an object of the present invention to provide compositions and treatment methods that will help prevent the growth of aberrant microorganisms on the surface of the skin either before during or post infection.
Prebiotics are non-digestible food ingredients that stimulate the growth andior activity of bacteria in the digestive system in ways claimed to be beneficial to health. They were first identified and named by Marcel Robcrfroid in 1 995 (Dietwy modulation of the human colon/c ni/crab/ow: introducing the concept ofprehioiics. J Nutr. 1995 Jun;125(6): 1401-12. PMID).
Typically, prebiotics are carbohydrates (such as oligosaccharides), but the definition may include non-carbohydrates. The most prevalent forms of prebiotics arc nutritionally classed as soluble fibre. To some extent, many forms of dietary fibre exhibit some level ofprebiotic effect.
Roberfroid offered a refined definition in the 2007 Journal of Nutrition (Prehiotics: The Concept Revisited. J Nutr. 2007; 137: 8305) stating: "A prebiotic is a selectively fermented ingredient that allows specific changes, both in the composition and/or activity in the gastrointestinal microflora that confers benefits upon host well-being and health." As a functional food component, prebiotics, like probiotics, are conceptually intcrmediate between foods and drugs.
Currently the use of prebiotics is confined to dietary use.
SUMMARY OF THE INVENTION
An object of the present invention is to provide a flexible webbing such as a surgical tissue or disposable wipe comprising one or more prebiotics. It is anticipated that gentle rubbing of the surface of the skin with the webbing will transfer the prebiotic from the webbing to the skin.
Advantageously the application of the prebiotic to the skin will promote the growth of "friendly" microorganism on the skin. Such growth may prevent the growth of non-friendly microorganisms on the skin, or reduce the growth of non-friendly microorganisms by competition between the friendly and non-friendly microorganisms.
Advantageously a webbing comprising one or more prebiotics allows for easy storage, use, and application of the prebiotic to the skin.
A thrther advantage is that using the wipe it is possible to apply the prebiotic either in a highly specific and/or localised way or generally over a large surface area.
The prebiotic can be applied only to the surface of the webbing, or can be impregnated into the webbing. The prebiotic can be applied to the webbing as a solid, liquid or suspension.
In a preferred embodiment the prebiotic is selected from one or more of the following group: soluble fibre carbohydrate, fructooligosaccharide, galactooligosacharides or man nan oligosaccharides.
In a most preferred embodiment the prebiotic is inulin.
The flexible webbing can be made from a biodegradable material, non-biodegradable material, or a mixture of biodegradable and non-biodegradable material.
Preferably the biodegradable material is one or more of the following: a wood pulp, a cellulose, a corn starch, a cotton, a silk, a viscose, or functional derivative thereof, or a combination of any one or more of a wood pulp, a cellulose, a corn starch, a cotton, a silk, a viscose or a naturally derived product comprising or functional derivative thereof Preferably the non-biodegradable material is made from synthetic fibres of the following groups: polyamides, polyester, acrylic, polyolefin, rayon or cellulose acetate.
The optionally the flexible webbing may also be made using spunlaee, airlaid, wet laid, non-woven, woven or scrim reinforced methods.
It is anticipated that the webbing comprising one or more prebiotics may have medical use and cosmetic uses for the prevention and treatment of aberrant microorganisms on the skin.
It is further anticipated that the webbing comprising one or more prebioties may have a specific use in the prevention and treatment of infection caused by nappy rash and incontinence in juveniles and adults.
Embodiments of the present invention will now be described in more detail.
EXAMPLE
This invention relates to a flexible webbing to which has been added one or more prebioties.
The human skin is susceptible to many different types of aberrant skin infections which include infections by viruses, bacteria and fungi. Such infections can manifest as acne, skin blemishes and rashes. The most common form of skin problem in young adults is as a result of acne. Acne is when the sebaeeous glands in the skin become blocked with sebum. The sebaceous glands and surrounding area can in some instances get infected by bacteria such as P. aenes, P. granulosum and members of the staphylococcus family. Treatment of infected acne is with antibacterial compounds such as topical benzoyl peroxide. retinoids, antibiotics, or azelaic acid.
Nappy rash is causes the baby's skin to become sore and irritated in the area around the nappy, and covered in pink or red spots or blotches. Nappy rash is usually caused by your baby's skin coming into contact with urine and faeces in their nappy and can be a cause of a bacterial or fungal skin infection. Similar problems are associated with juveniles and adults who suffer from incontinent. One commonly used means to prevent infection of the skin where nappy rash is likely to occur is to protect that area of the skin with a barrier cream such as zinc oxide based creams. In more severe cases it may be necessary to treat the condition with medicaments described above.
Other examples of bacterial and fungal skin infections include Athlete's foot, Onychomycosis, Ringworm, Intertrigo, Pityriasis versicolor, Thrush, Staphylococcus aureus, Streptococcus pyogenes, Haemophilus, Helicobacter pylon Klebsiella rhinoscleromatis.
It is often the case that these conditions are treated with anti fungal medicines (e.g. clotrimazole, Econazole, ketoconazole, miconazole, sulconazole, nystatin), steroids such as corticosteroids and antibiotics.
However, the above treatments all rely on either a skin barrier being formed that prevents infection or the treatment of an infection with an antiseptic or medicament. Tt is therefore an object of the present invention to provide a composition and treatment methods that will help prevent the growth of aberrant microorganisms on the surface of the skin either before during or post infection.
Prebiotics are non-digestible food ingredients that stimulate the growth and/or activity of bacteria in the digestive system in ways claimed to be beneficial to health. Typically, prebioties are carbohydrates (such as oligosacchanides, but the definition may include non-carbohydrates.
The most prevalent forms of prebiotics are nutritionally classed as soluble fiber. Dietary sources of prcbiotics include soybeans, inulin sources (such as Jerusalem artichoke, jicama, and chicory root), raw oats, unrefined wheat, unrefined barley and yacon.
Longer-chain prebiotics, e.g. Inulin, contain 9-64 links per saccharide molecule, and tend to be fermented more slowly, nourishing bacteria predominantly in the left-side colon. Full-spectrum prebiotics provide the fill range of molecular link-lengths from 2-64 links per molecule, and nourish bacteria throughout the colon, e.g. Oligofructose-Enriched Inulin (OEI).
The prebiotic definition does not emphasize a specific bacterial group. Generally, however, it is assumed that a prcbiotic should increase the number and/or activity of bifidobacteria and lactic acid bacteria. Prebiotic oligosaccharides are incrcasingly added to foods for their health benefits.
Some oligosaccharides that arc used in this manner arc fructooligosaccharidcs (FOS), xyloo ligosaccharides (XOS),polydextrose and galactooligosaccharides (GOS). Some monosaccharides such as tagatose arc also used Chemically, dietary fiber consists of non-starch polysaccharides suchas arabinoxylans, cellulose and many other plant components such as resistant dextrins, inulin, lignin, waxes, chitins, pectins, bcta-glucans and oligosaccharidcs. [U Inulin is chemically defined as oligosaccharides occurring naturally in most plants, inulins have nutritional value as carbohydrates, or more specifically as fructans.polymerfructoselaulin is typically extracted by manufacturers from chicory roots or Jerusalem artichokes Inulin in the gut promotes an increase in thc mass and health of intcstinal Lactobacillus and Bitidohacterium populations.
Fructooligosaccharides (FOS) also sometimes called oligofructose or oligofnictan, is a class of oligosaccharides used as an alternative sweetener. The term oligosaccharidc refers to a short chain of sugar molecules (in the case of FOS, fructose molecules). Two different classes of fructooligosaccharidc (FOS) mixtures arc produced commercially, based on inulin degradation or transfructosylation processes.
FOS can be produced by degradation of inulin, or polyftuctosc, a polymer of D-fructose residues linked by f3(2-*1) bonds with a terminal ri(l-*2) linked D-glucose. The degree of polymerization of inulin ranges from 10 to 60. Inulin can be degraded enzymatically or chemically to a mixture of oligosaceharides with the general structure Glu-(Fru)1, (GF) and Frum (F111). with n and mranging from I to 7. The main components of commercial products are kestose (GF2), nystose (GF3), fructosylnystose (GF4), biflurcose (OH), inulobiose (F2), inulotriose (F3), and inulotctraosc (F4).
The second class of FOS is prepared by the transfructosylation action of a -fructosidase of Aspergillus niger on sucrosc. The resulting mixturc has the general formula of GF, with ii ranging from Ito 5. Contrary to the inulin-derived FOS, not only is there (l -÷2) binding but other linkages do occur, however, in limited numbers. In the colon they are fermented by anaerobic bacteria. Fructooligosaccharides are more soluble than inulins and are, therefore, sometimes used as an additive to yoghur tand other (dairy) products.
FOS is extracted from fruits and vegetables such as bananas, onions, chicory root, garlic, asparagus, barley, wheat, jIeama, tomatoes, and leeks. The Jerusalem artichoke and its relative yaeOn have been found to have the highest concentrations of FOS of cultured plants. All inulin-type prebiotics, including FOS, are generally thought to stimulate the growth of Bifidobacteria species. Bfldohacteria are considered friendly" bacteria.
Galacto-oligosaceharides (GOS), also known as oligogalactosyllactose, oligogalactose, oligolactose or transgalactooligosaccharides (TOS), belong, because of their indigestible nature, to the group ofprebiotics. GOS generally comprise a chain of galactose units that arise through consecutive transgalactosylation reactions, with a terminal glucose unit. Commersial derivatives of 005 include Oligomate 55 in syrup form, Oligomate 5SF in powder form and TOS-lOO a purified version of 99% oligosaccharide content syrup (Cup-Oligo H70) and powder format (Cup-Oligo P), Vivinal GOS (in a syrup format containing 57% oligosaccharides on dry matter and in a powder format containing 29% oligosaccharides on dry matter), Bimuno, with 52% galaeto-oligosaceharide content on dry matter and syrup.
Mannan-oligosaccharides are widely used in nutrition. MOS has been shown to improve gastrointestinal health as well as overall health, thus improving wellbeing, energy levels and performance. Most MOS products are derive from the cell wall of the yeast, Saccharomyces cerevisiae. MOS has been shown to reduction in the prevalence and concentration of different strains of salmonella and E. coli and increase lactobaeilli and bifidobacteria in the gut.
Webbing in the form of wipes and tissues are used to wipe surfaces or skin or as applicators for surfaces or skin. These tissues and wipes can be made from biodegradable or non-biodegradable materials or a mixture of both.
Nautural fibres are biodegradabe fibres and are general derived from vegetable products (but animal products are also available. Non limiting examples include fibres derived from examples of which are wood pulp, cellulose, corn starch, cotton, silk, and viscose.
Non biodegradable materials are generally synthetic in nature and can be made into fibres or non woven materials, and can be made from a diverse range of chemical groups. For example synthetic fibres can be made from polyamides, polyester, acrylic, polyolefin, rayon or cellulose acetatc. Examples of sub groups of these chemicals include polyaamides, polyethylene terephihalate, polyacrylonitrile, vinyl acetate, methyl acrylate, polyethylene, cellulose acetate, raylon, mondacrylie, polyvinyl chloride, or polyvinylidene chloride, Spunlacing is a process of entangling a web of loose fibers on a porous belt or moving perforated or patterned screen to form a sheet structure by subjecting the fibers to multiple rows of fine high-pressure jets of water. Various steps are of importance in the hydroentangling process.
While some of them are typical in a nonwoven process, some of them arc uniquc to the process of spunlacing. The steps characteristic for producing hydroentangled nonwoven fabric include: Precursor web formation, Web entanglcment, Water circulation and Web drying Air-laid paper is a textile-like material categorized as a nonwoven fabric made from fluff pulp.
Compared with normal wet-laid paper and tissue, air-laid paper is very bulky, porous and soft. It has good water absorption properties and is much stronger compared with normal tissue. Unlike the normal papermaking process, air-laid paper does not use water as the carrying medium for the fibre. Fibres arc carried and formed to the structure of paper by air. The air-laid structure isisotropic. The raw material is long fibered softwood fluff pulp in roll form.
Wet-laid nonwovens are nonwovens made by a modified papermaking process. That is, the fibers to be used are suspended in water. Papermaking fibers being short and fine are able to pack together into a dense structure. Chemical groups attached to their surfaces are able to form hydrogen bonds with similar groups on neighboring fibers very easily. In paper, the fibers overlap randomly and pack densely.
Nonwoven fabric is a fabric-like material made from long fibres, bonded together by chemical, mechanical, heat or solvent treatment. Nonwoven fabrics are broadly defined as sheet or web structures bonded together by entangling fibre or filaments (and by perforating films) mechanically, thermally or chemically. They are flat, porous sheets that are made directly from separate fibres or from molten plastic or plastic film. They are not made by weaving or knitting and do not require converting the fibres to yarn.
Nonwoven fabrics provide specific functions such as absorbency, liquid repellence, resilience, stretch, softness, strength, flame retardancy, washability, cushioning, filtering, use as a bacterial barrier and sterility.
A woven is material is formed by weaving. It only stretches in the bias directions (between the warp and weft directions), unless the threads are elastic. Woven materials usually frays at the edges, unless measures arc taken to counter this, such as the use of pinking shears or hemming.
Woven fabrics arc worked on a loom and made of many threads wovcn on a warp and a wcft. It is strctchy only along thc bias.
The technique of scrim as a reinforce where scrim is a strong loose weave of fibres laminated into the matcrial to provide extra strcngth and stability.
An embodiment of the present invention is a flexible webbing, characterised in that the webbing comprises at least one prebiotic.
Optionally the prebiotic may bc placed on the surfacc, or within the webbing. Prcfcrably the prebiotic is a carbohydrate or oligosaccharidc and is selected from onc or more of the following group: soluble fibre carbohydrate, fructooligosaccharide, galactooligosacharidcs or mannan oligosaccharides. Non limiting examples of these groups include oligofructose (oligofructan), inulin, oligomate 55, ologomate SSp, TOS -100, cup-oligo H70, alpha glucan oligosaccharide, or bimuno, or functional derivatives thcrcof Preferably the webbing is made from a biodegradable material, non-biodegradable material, or a mixture of biodegradable and non-biodegradable material. When the webbing comprises a biodegradable material it is optional that this material is a naturally derived product, or derivative thereof. Examples of such materials includewood pulp, cellulose, com starch, cotton, silk, viscose. When the webbing comprises a non biodcgradablc it is a optional that the material is made from polyamides, polyester, acrylic, polyolefin, rayon or ccllulosc acetate non limiting examples includc polyaam ides, polycthylenc tcrephthalate, polyacrylonitrile, vinyl acctatc, mcthyl acrylate, polyethylene, cellulose acetate, raylon, mondacrylic, polyvinyl chloride, or polyvinylidene chloride.
Optionally the webbing can be made using spunlace, airlaid, wet laid, non-woven, woven or scrim reinforced methods.Optionally the prebiotic is added to the webbing in a powdered form, a liquid form or suspension form. In its post preferred embodiment the prebiotie is inulin or alpha glucan oligosaeeharide.
In a preferred embodiment the prebiotic is formed into a micro emulsion prior to incorporation into the webbing. The process comprises A) Mix phase A comprising Prebiotic (about 0.5% to 1% v/v),TECO Wipe DF PE (about 5% v/v), isohexadecane (about 0.5% v/v) perfume (optional) (about "% v/v) with phase B comprising demineralised water (about 6%), B) Stir until a micro-emulsion phase is obtained C) Add phase C) while stirring (EUXYL PE 9010 (pherioxyethanol, ethylhehylglyccrin) (about 0.4%).
D) Dilute with phase D comprising demineralised water (about 86.4% v/v), glycerine (0 to 0.5% v/v depending on concentration of prebiotic) panthenol (about 0.5%v/v) It is also anticipated that the compositions described above will find use in medicine including the treatment of aberrant skin conditions and in cosmetic uses to promotr the growth of beneficial microorganisms on the surface of the skin, said method comprising: a. Applying the flexible webbing according to any one of claims Ito 14 to the surface of unbroken skin such that the prcbiotic is transferred from the webbing to the skin, and b. Repeat application when necessary.
In a second embodiment it is envisaged a kit for applying a prebiotic to a surface, comprising the flexible webbing as described above and a closure to protect unused webbing.
It is intended that the claims as filed also form part of the description.
Claims (1)
- <claim-text>Claims 1. A flexible webbing, characterised in that the webbing comprises at least one prebiotic.</claim-text> <claim-text>2. The flexible webbing according to claim 1, characterised in that the prebiotie is on the surface, or within the webbing.</claim-text> <claim-text>3. The flexible webbing of claim 1 or claim 2, charactcrised in that the prebiotic is a carbohydrate or oligosaceharide.</claim-text> <claim-text>4. The flexible webbing according to claim 1, claim 2 or claim 3, characterised in that the prebiotic is selected from one or more of the following group: soluble fibre carbohydrate, fructooligosaccharide, galactooligosacharides or mannan oligosaccharides.</claim-text> <claim-text>5. The flexible webbing according to anyone or more of the preceding claims, characterised in that the prebiotic is selected from one or more of the following: oligofructose (oligofructan), inulin, oligomate 55, ologomate SSp, TOS -100, cup-oligo H70, alpha gluean oligosaccharidc, or bimuno, or functional denvatives thereof 6. The flexible webbing according to any one or more of claims I to 5, characterised in that the webbing is a biodegradable material, non-biodegradable material, or a mixture of biodegradable and non-biodegradable materiaL 7. The flexible webbing according to claim 6, eharacterised in that the biodegradable material is a naturally derived product, or derivative thereof 8. The flexible webbing according to claim 7, charaeterised in that the naturally derived product is, a wood pulp, a cellulose, a corn starch, a cotton, a silk, a viscose, or ifinctional derivative thereof, or a combination of any one of a wood pulp, a cellulose, a corn starch, a cotton, a silk, a viscose or a naturally derived product comprising or functional derivative thereof 9. The flexible webbing according to claim 6, characterised in that the non biodegradable material is a synthetic fibre including synthetic fibres made from one or more of the following groups: polyamides, polyester, acrylic, polyolefin, rayon or cellulose acetate.10. The flexible webbing according to claim, charaeterised in that the non biodegradable material is selected from one or more of the following groups: polyaamides, polyethylene terephthalate, polyacrylonitrile, vinyl acetate, methyl aerylate, polyethylene, cellulose acetate, raylon, mondacrylie, polyvinyl chloride, or polyvinylidene chloride, 11. The flexible webbing according to claim 6, characterised in that webbing comprises a biodegradable and a non biodegradable material is selected from the the materials of claims 7 to 10.12. The flexible webbing according to any one or more of the proceeding claims, characterised in that the webbing is made using the spunlace, airlaid, wct laid, non-woven, woven or scrim reinforced methods.13. The flexible webbing according to any one of the proceeding claims, characterised in that the prebiotic is added to the webbing in a powdered form, a liquid form or suspension form.14. The flexible webbing according to any one of the proceeding claims, characterised in that the prebiotic composition is inulin or alpha glucan oligosaccharide.15. The flexible webbing according to any one of the proceeding claims, characterised in that the prebiotic is about 0.5% to 1% of the webbing solution.16. A flexible webbing according to and one of claims Ito 15 for use as a medicament.17. A flexible webbing according to any one of claims Ito 15 in the treatment or prevention of aberrant infection of the skin.18. A method of promoting the growth of beneficial microorganisms on the surface of the skin, said method comprising: c. Applying the flexible webbing according to any one of claims Ito 15 to the surface of unbroken skin such that the prebiotic is transferred from the webbing to the skin, and d. Repeat application when necessary.19. A kit for applying a prebiotic to a surface, comprising the flexible webbing according to any one of claims 1 to 15 aad a closure to protect unused webbing.20. A composition substantially as described according to the description and drawings herein.</claim-text>
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1117415.8A GB2495491A (en) | 2011-05-23 | 2011-05-23 | Pre-biotic skin wipe |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1117415.8A GB2495491A (en) | 2011-05-23 | 2011-05-23 | Pre-biotic skin wipe |
Publications (2)
Publication Number | Publication Date |
---|---|
GB201117415D0 GB201117415D0 (en) | 2011-11-23 |
GB2495491A true GB2495491A (en) | 2013-04-17 |
Family
ID=45091763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1117415.8A Withdrawn GB2495491A (en) | 2011-05-23 | 2011-05-23 | Pre-biotic skin wipe |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2495491A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9539344B2 (en) | 2014-09-30 | 2017-01-10 | Kimberly-Clark Worldwide, Inc. | Creped prebiotic tissue |
US10441603B2 (en) | 2014-09-30 | 2019-10-15 | Kimberly-Clark Worldwide, Inc. | Synergistic prebiotic composition |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005110504A1 (en) * | 2004-04-30 | 2005-11-24 | Kimberly-Clark Worldwide, Inc. | Personal care products and methods for inhibiting the adherence of flora to skin |
DE102004037505A1 (en) * | 2004-08-03 | 2006-02-23 | Henkel Kgaa | Prebiotic Intimate Care |
WO2008028603A1 (en) * | 2006-09-09 | 2008-03-13 | Cognis Ip Management Gmbh | Oral and/or topical compositions |
US20090155325A1 (en) * | 2007-12-14 | 2009-06-18 | Kimberly-Clark Worldwide, Inc. | Formulation and products for promoting skin cleanliness and health |
WO2010074614A1 (en) * | 2008-12-22 | 2010-07-01 | Sca Hygiene Products Ab | Sanitary article comprising an improved delivery device |
WO2010123419A1 (en) * | 2009-04-20 | 2010-10-28 | Sca Hygiene Products Ab | Packaged wipe or hygiene tissue |
GB2472379A (en) * | 2009-07-15 | 2011-02-09 | Oskia Skincare Ltd | Topical cosmetic formulation comprising MSM, a vitamin and a carbohydrate |
US20110088711A1 (en) * | 2009-06-24 | 2011-04-21 | L'oreal | Wipe with an emulsion containing a thickening polymer and a hydrophobic modified inulin |
-
2011
- 2011-05-23 GB GB1117415.8A patent/GB2495491A/en not_active Withdrawn
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005110504A1 (en) * | 2004-04-30 | 2005-11-24 | Kimberly-Clark Worldwide, Inc. | Personal care products and methods for inhibiting the adherence of flora to skin |
DE102004037505A1 (en) * | 2004-08-03 | 2006-02-23 | Henkel Kgaa | Prebiotic Intimate Care |
WO2008028603A1 (en) * | 2006-09-09 | 2008-03-13 | Cognis Ip Management Gmbh | Oral and/or topical compositions |
US20090155325A1 (en) * | 2007-12-14 | 2009-06-18 | Kimberly-Clark Worldwide, Inc. | Formulation and products for promoting skin cleanliness and health |
WO2010074614A1 (en) * | 2008-12-22 | 2010-07-01 | Sca Hygiene Products Ab | Sanitary article comprising an improved delivery device |
WO2010123419A1 (en) * | 2009-04-20 | 2010-10-28 | Sca Hygiene Products Ab | Packaged wipe or hygiene tissue |
US20110088711A1 (en) * | 2009-06-24 | 2011-04-21 | L'oreal | Wipe with an emulsion containing a thickening polymer and a hydrophobic modified inulin |
GB2472379A (en) * | 2009-07-15 | 2011-02-09 | Oskia Skincare Ltd | Topical cosmetic formulation comprising MSM, a vitamin and a carbohydrate |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9539344B2 (en) | 2014-09-30 | 2017-01-10 | Kimberly-Clark Worldwide, Inc. | Creped prebiotic tissue |
US9744248B2 (en) | 2014-09-30 | 2017-08-29 | Kimberly-Clark Worldwide, Inc. | Creped prebiotic tissue |
US10441603B2 (en) | 2014-09-30 | 2019-10-15 | Kimberly-Clark Worldwide, Inc. | Synergistic prebiotic composition |
Also Published As
Publication number | Publication date |
---|---|
GB201117415D0 (en) | 2011-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bashari et al. | Cellulose‐based hydrogels for personal care products | |
Teixeira et al. | Electrospun nanocomposites containing cellulose and its derivatives modified with specialized biomolecules for an enhanced wound healing | |
Serpa et al. | Vegetable nanocellulose in food science: A review | |
Zhang et al. | Improving the performance of edible food packaging films by using nanocellulose as an additive | |
Żywicka et al. | Modification of bacterial cellulose with quaternary ammonium compounds based on fatty acids and amino acids and the effect on antimicrobial activity | |
EP1267891B1 (en) | Antiadhesive carbohydrates | |
ES2180321T5 (en) | Carbohydrate blends | |
Giri et al. | A brief review on extraction of nanocellulose and its application | |
CN104164754A (en) | Chitin non-woven fabric and application thereof | |
CN106616187A (en) | Solid beverage capable of assisting to lower hypertension, hyperglycemia and hyperlipidemia | |
GB2498543A (en) | Topical prebiotic powder composition and uses thereof | |
CN103340722A (en) | Sanitary towel good in water-absorbing performance | |
WO2009036483A1 (en) | Non-woven biodegradable hygiene product | |
Rashki et al. | Cellulose-based nanofibril composite materials as a new approach to fight bacterial infections | |
GB2495491A (en) | Pre-biotic skin wipe | |
Banerjee et al. | Recent advances in nanobiotechnology for medical textiles | |
Tanpichai et al. | Enhancement of the mechanical properties and water barrier properties of thermoplastic starch nanocomposite films by chitin nanofibers: Biodegradable coating for extending banana shelf life | |
Han et al. | Novel double cross-linked acrylic acid/bagasse cellulose porous hydrogel for controlled release of citral and bacteriostatic effects | |
CN102839569B (en) | A kind of chitosan wet tissue paper and preparation method thereof | |
AU2014407509B2 (en) | Synergistic prebiotic composition | |
Kopańska et al. | Combination of polylactide with cellulose for biomedical applications: a recent overview | |
Sutjarittangtham et al. | Mechanically improved antibacterial polycaprolactone/propolis electrospun fiber mat by adding bacterial nanocellulose | |
CN101962860A (en) | Weaving method and woven fabric thereof | |
CN106619146A (en) | Baby skin care wipes | |
Tyagi et al. | Future prospects of biobased materials |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |